Submission Details
| 510(k) Number | K032254 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 22, 2003 |
| Decision Date | August 29, 2003 |
| Days to Decision | 38 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Statement |
K032254 is an FDA 510(k) clearance for the IBL C1Q-CIC CIA TEST, a Complement C1q, Antigen, Antiserum, Control (Class II — Special Controls, product code DAK), submitted by Ibl GmbH (East Stroudsburg, US). The FDA issued a Cleared decision on August 29, 2003, 38 days after receiving the submission on July 22, 2003. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5240.
| 510(k) Number | K032254 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 22, 2003 |
| Decision Date | August 29, 2003 |
| Days to Decision | 38 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Statement |
| Product Code | DAK — Complement C1q, Antigen, Antiserum, Control |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.5240 |